Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 May 2023
Price :
$35
*
At a glance
- Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms CTII-nCoV
- 22 May 2023 Status changed from active, no longer recruiting to completed.
- 20 Jul 2020 Results published in the THE LANCET
- 20 Apr 2020 Status changed from recruiting to active, no longer recruiting.